| Literature DB >> 32183043 |
Vanessa Santos-Sánchez1, Juan Antonio Córdoba-Doña2, Javier García-Pérez3,4, Antonio Escolar-Pujolar5, Lucia Pozzi1, Rebeca Ramis3,4.
Abstract
Residential proximity to industrial facilities that release pollutants is a source of exposure to a high number of toxics, many of them known or suspected carcinogens. The objective of the study was to analyze the association between lung, larynx, bladder, and kidney cancer mortality and deprivation in areas proximate to polluting industrial facilities in Cadiz, a highly industrialized province in Spain. An ecological study at census tract level was carried out to estimate the mortality rates associated with deprivation and proximity to polluting industrial facilities (1-5 km) using the Besag-York-Mollié model. The results show a negative social gradient for lung and larynx cancers in males and greater risk of lung cancer was observed in the least deprived areas in females. These associations were found regardless the distance to industrial facilities. Increasing excess risk (relative risk; 95% credibility interval) of lung cancer for males (1.09; 1.02-1.16 at 5 km vs 1.24; 1.08-1.41 at 1 km) and bladder cancer for males (1.11; 1.01-1.22 at 5 km vs 1.32; 1.08-1.60 at 1 km) and females (1.32; 1.04-1.69 at 4 km vs 1.91; 1.28-2.86 at 1 km) was found as proximity to polluting industrial facilities increased. For kidney cancer, high risks were observed near such facilities for both sexes. Knowing the possible influence of industrial pollution and social inequalities over cancer risk allows the definition of policies aimed at reducing the risk.Entities:
Keywords: cancer mortality; health inequalities; industrial pollution
Year: 2020 PMID: 32183043 PMCID: PMC7142953 DOI: 10.3390/ijerph17061860
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Locations of the 26 industrial facilities analyzed. E-PRTR—European Pollutant Release and Transfer Register.
Relative risks (RRs) for deprivation index adjusted for distance of exposure for the male population.
| Cause | DI | 1 km | 2 km | 3 km | 4 km | 5 km | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exposed CT = 46 | Exposed CT = 151 | Exposed CT = 224 | Exposed CT = 297 | Exposed CT = 413 | ||||||||||||
|
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI | ||
| Lung cancer | 1 | 174 | 1.00 | - | 390 | 1.00 | - | 542 | 1.00 | - | 694 | 1.00 | - | 1026 | 1.00 | - |
| 2 | 74 |
| 1.09–1.32 | 372 |
| 1.08–1.32 | 662 |
| 1.08–1.31 | 876 |
| 1.07–1.31 | 1233 |
| 1.07–1.31 | |
| 3 | 65 |
| 1.14–1.39 | 418 |
| 1.13–1.38 | 610 |
| 1.13–1.37 | 803 |
| 1.13–1.37 | 1085 |
| 1.13–1.38 | |
| 4 | 125 |
| 1.21–1.47 | 448 |
| 1.20–1.46 | 536 |
| 1.21–1.47 | 704 |
| 1.20–1.47 | 934 |
| 1.21–1.47 | |
| 5 | 143 |
| 1.24–1.51 | 306 |
| 1.23–1.50 | 412 |
| 1.23–1.50 | 512 |
| 1.23–1.50 | 607 |
| 1.24–1.51 | |
| Laryngeal cancer | 1 | 18 | 1.00 | - | 38 | 1.00 | - | 52 | 1.00 | - | 68 | 1.00 | - | 94 | 1.00 | - |
| 2 | 5 |
| 1.06–1.70 | 37 |
| 1.05–1.68 | 74 |
| 1.05–1.68 | 95 |
| 1.05–1.68 | 129 |
| 1.05–1.68 | |
| 3 | 10 |
| 1.36–2.14 | 50 |
| 1.35–2.12 | 73 |
| 1.35–2.12 | 97 |
| 1.35–2.12 | 142 |
| 1.35–2.12 | |
| 4 | 20 |
| 1.47–2.31 | 53 |
| 1.47–2.31 | 73 |
| 1.47–2.30 | 101 |
| 1.46–2.29 | 121 |
| 1.47–2.30 | |
| 5 | 11 |
| 1.67–2.62 | 33 |
| 1.66–2.61 | 46 |
| 1.66–2.61 | 61 |
| 1.65–2.59 | 76 |
| 1.66–2.61 | |
| Bladder cancer | 1 | 45 | 1.00 | - | 100 | 1.00 | - | 145 | 1.00 | - | 188 | 1.00 | - | 265 | 1.00 | - |
| 2 | 16 | 1.12 | 0.96–1.30 | 98 | 1.11 | 0.95–1.29 | 170 | 1.10 | 0.95–1.28 | 215 | 1.10 | 0.95–1.28 | 282 | 1.10 | 0.95–1.28 | |
| 3 | 19 |
| 1.03–1.39 | 91 |
| 1.02–1.37 | 138 |
| 1.02–1.37 | 174 |
| 1.02–1.37 | 250 |
| 1.02–1.37 | |
| 4 | 32 |
| 1.03–1.39 | 99 |
| 1.02–1.38 | 127 |
| 1.02–1.38 | 168 |
| 1.02–1.38 | 221 |
| 1.02–1.38 | |
| 5 | 29 | 1.04 | 0.89–1.21 | 70 | 1.03 | 0.88–1.20 | 89 | 1.02 | 0.88–1.20 | 103 | 1.03 | 0.88–1.20 | 123 | 1.03 | 0.88–1.21 | |
| Kidney cancer | 1 | 15 | 1.00 | - | 31 | 1.00 | - | 41 | 1.00 | - | 54 | 1.00 | - | 76 | 1.00 | - |
| 2 | 5 | 0.99 | 0.76–1.28 | 17 | 0.97 | 0.74–1.25 | 38 | 0.96 | 0.74–1.24 | 56 | 0.95 | 0.74–1.24 | 76 | 0.96 | 0.74–1.24 | |
| 3 | 9 | 1.10 | 0.86–1.43 | 38 | 1.08 | 0.84–1.39 | 47 | 1.08 | 0.83–1.39 | 56 | 1.08 | 0.83–1.39 | 69 | 1.08 | 0.84–1.39 | |
| 4 | 7 | 0.96 | 0.73–1.25 | 23 | 0.94 | 0.72–1.22 | 30 | 0.94 | 0.72–1.23 | 37 | 0.94 | 0.72–1.22 | 53 | 0.94 | 0.72–1.23 | |
| 5 | 7 | 0.80 | 0.61–1.07 | 13 | 0.79 | 0.60–1.05 | 16 | 0.79 | 0.60–1.05 | 23 | 0.79 | 0.59–1.05 | 29 | 0.80 | 0.60–1.06 | |
Models were estimated separately for each type of cancer and for the different cut-off points of the exposure variable. Statistically significant results are in bold. DI—deprivation index level; Exposed CT—number of census tracts at a distance less than that considered; n—number of observed cancer deaths; CI—credibility intervals.
RRs for deprivation index adjusted for distance of exposure for the female population.
| Cause | DI | 1 km | 2 km | 3 km | 4 km | 5 km | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exposed CT = 46 | Exposed CT = 151 | Exposed CT = 224 | Exposed CT = 297 | Exposed CT = 413 | ||||||||||||
|
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI | ||
| Lung cancer | 1 | 38 | 1.00 | - | 72 | 1.00 | - | 89 | 1.00 | - | 110 | 1.00 | - | 151 | 1.00 | - |
| 2 | 3 | 0.91 | 0.75–1.11 | 30 | 0.89 | 0.74–1.08 | 63 | 0.89 | 0.73–1.08 | 93 | 0.89 | 0.73–1.07 | 124 | 0.89 | 0.73–1.07 | |
| 3 | 11 |
| 0.67–0.99 | 37 |
| 0.65–0.97 | 55 |
| 0.65–0.97 | 71 |
| 0.65–0.97 | 96 |
| 0.65–0.97 | |
| 4 | 10 |
| 0.63–0.94 | 36 |
| 0.62–0.92 | 44 |
| 0.62–0.92 | 61 |
| 0.62–0.92 | 76 |
| 0.62–0.92 | |
| 5 | 9 |
| 0.51–0.79 | 22 |
| 0.50–0.78 | 27 |
| 0.50–0.78 | 32 |
| 0.50–0.78 | 39 |
| 0.51–0.78 | |
| Laryngeal cancer | 1 | 2 | 1.00 | - | 2 | 1.00 | - | 3 | 1.00 | - | 3 | 1.00 | - | 7 | 1.00 | - |
| 2 | 0 | 0.79 | 0.27–2.28 | 1 | 0.78 | 0.27–2.25 | 2 | 0.80 | 0.28–2.31 | 3 | 0.81 | 0.28–2.34 | 4 | 0.80 | 0.28–2.31 | |
| 3 | 0 | 0.88 | 0.30–2.57 | 2 | 0.90 | 0.31–2.60 | 4 | 0.90 | 0.31–2.60 | 4 | 0.90 | 0.31–2.60 | 5 | 0.90 | 0.31–2.59 | |
| 4 | 0 | 0.81 | 0.26–2.49 | 1 | 0.83 | 0.27–2.55 | 1 | 0.81 | 0.26–2.51 | 2 | 0.83 | 0.27–2.55 | 3 | 0.81 | 0.26–2.51 | |
| 5 | 0 | 1.19 | 0.40–3.56 | 0 | 1.23 | 0.41–3.69 | 1 | 1.21 | 0.40–3.62 | 1 | 1.25 | 0.41–3.76 | 2 | 1.20 | 0.40–3.57 | |
| Bladder cancer | 1 | 14 | 1.00 | - | 22 | 1.00 | - | 33 | 1.00 | - | 42 | 1.00 | - | 52 | 1.00 | - |
| 2 | 3 | 0.84 | 0.58–1.19 | 19 | 0.80 | 0.56–1.14 | 30 | 0.79 | 0.56–1.13 | 34 | 0.79 | 0.55–1.13 | 40 | 0.80 | 0.56–1.13 | |
| 3 | 5 | 1.14 | 0.82–1.59 | 19 | 1.10 | 0.79–1.53 | 25 | 1.09 | 0.78–1.51 | 34 | 1.10 | 0.79–1.53 | 46 | 1.10 | 0.79–1.53 | |
| 4 | 3 | 1.03 | 0.73–1.45 | 13 | 1.01 | 0.72–1.41 | 16 | 1.01 | 0.72–1.41 | 24 | 1.01 | 0.72–1.41 | 35 | 1.01 | 0.72–1.42 | |
| 5 | 6 | 0.87 | 0.60–1.26 | 8 | 0.85 | 0.59–1.23 | 10 | 0.84 | 0.58–1.22 | 13 | 0.85 | 0.58–1.23 | 17 | 0.86 | 0.59–1.25 | |
| Kidney cancer | 1 | 8 | 1.00 | - | 17 | 1.00 | - | 23 | 1.00 | - | 30 | 1.00 | - | 47 | 1.00 | - |
| 2 | 5 | 1.18 | 0.85–1.65 | 16 | 1.15 | 0.83–1.60 | 25 | 1.15 | 0.83–1.60 | 34 | 1.15 | 0.83–1.60 | 48 | 1.15 | 0.83–1.60 | |
| 3 | 1 | 0.83 | 0.58–1.20 | 12 | 0.81 | 0.57–1.17 | 13 | 0.82 | 0.57–1.18 | 23 | 0.81 | 0.57–1.17 | 37 | 0.81 | 0.57–1.17 | |
| 4 | 7 | 0.86 | 0.60–1.23 | 18 | 0.84 | 0.59–1.21 | 22 | 0.85 | 0.59–1.22 | 28 | 0.85 | 0.59–1.22 | 31 | 0.85 | 0.59–1.22 | |
| 5 | 3 | 0.68 | 0.45–1.02 | 6 | 0.67 | 0.45–1.00 | 6 | 0.68 | 0.45–1.02 | 8 | 0.68 | 0.45–1.01 | 11 | 0.67 | 0.45–1.01 | |
Models were estimated separately for each type of cancer and for the different cut-off points of the exposure variable. Statistically significant results are in bold.
RRs of mortality from lung, laryngeal, bladder and kidney cancers adjusted for deprivation index in census tracts situated near polluting industrial facilities.
| Cause | 1 km | 2 km | 3 km | 4 km | 5 km | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exposed CT = 46 | Exposed CT = 151 | Exposed CT = 224 | Exposed CT = 297 | Exposed CT = 413 | |||||||||||
|
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI |
| RR | 95% CI | |
| Lung cancer | |||||||||||||||
| Men | 581 |
| 1.08–1.41 | 1934 |
| 1.05–1.24 | 2762 |
| 1.04–1.20 | 3589 |
| 1.04–1.19 | 4885 |
| 1.02–1.16 |
| Women | 71 | 1.18 | 0.91–1.54 | 197 | 0.95 | 0.80–1.13 | 278 | 0.92 | 0.79–1.08 | 367 | 0.92 | 0.80–1.07 | 486 | 0.88 | 0.77–1.01 |
| Laryngeal cancer | |||||||||||||||
| Men | 64 | 1.19 | 0.88–1.59 | 211 | 1.07 | 0.89–1.28 | 318 | 1.11 | 0.95–1.31 | 422 | 1.13 | 0.98–1.31 | 562 | 1.09 | 0.95–1.25 |
| Women | 2 | 1.67 | 0.36–7.78 | 6 | 1.48 | 0.53–4.14 | 11 | 1.89 | 0.78–4.55 | 13 | 1.72 | 0.73–4.02 | 21 | 1.99 | 0.91–4.37 |
| Bladder cancer | |||||||||||||||
| Men | 141 |
| 1.08–1.60 | 458 |
| 1.05–1.34 | 669 |
| 1.06–1.31 | 848 |
| 1.03–1.26 | 1141 |
| 1.01–1.22 |
| Women | 31 |
| 1.28–2.86 | 81 |
| 1.03–1.82 | 114 |
| 1.05–1.76 | 147 |
| 1.04–1.69 | 190 | 1.24 | 0.98–1.57 |
| Kidney cancer | |||||||||||||||
| Men | 43 |
| 1.12–2.17 | 122 | 1.23 | 0.99–1.54 | 172 | 1.18 | 0.97–1.44 | 226 | 1.18 | 0.98–1.42 | 303 | 1.14 | 0.95–1.35 |
| Women | 24 |
| 1.02–2.50 | 69 | 1.27 | 0.94–1.72 | 89 | 1.13 | 0.85–1.50 | 123 | 1.18 | 0.91–1.53 | 174 | 1.20 | 0.94–1.53 |
Models were estimated separately for each type of cancer and for the different cut-off points of the exposure variable. Statistically significant results are in bold.
RRs of mortality from lung, laryngeal, bladder and kidney cancers adjusted for deprivation index in census tracts situated near polluting industrial facilities that release Groups 1 and 2A substances.
|
| |||||||||||||||
|
|
|
|
|
|
| ||||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Lung cancer | |||||||||||||||
| Men | 581 |
| 1.07–1.40 | 1865 |
| 1.05–1.23 | 2164 |
| 1.03–1.19 | 3420 |
| 1.02–1.17 | 4663 |
| 1.01–1.15 |
| Women | 71 | 1.20 | 0.92–1.56 | 192 | 0.97 | 0.81–1.15 | 269 | 0.96 | 0.82–1.12 | 357 | 0.95 | 0.82–1.09 | 471 | 0.90 | 0.79–1.03 |
| Laryngeal cancer | |||||||||||||||
| Men | 64 | 1.20 | 0.89–1.61 | 204 | 1.09 | 0.91–1.31 | 304 | 1.14 | 0.97–1.34 | 413 |
| 1.01–1.35 | 542 | 1.12 | 0.98–1.28 |
| Women | 2 | 1.43 | 0.31–6.52 | 6 | 1.31 | 0.48–3.54 | 10 | 1.55 | 0.66–3.65 | 12 | 1.40 | 0.62–3.19 | 19 | 1.60 | 0.75–3.39 |
| Bladder cancer | |||||||||||||||
| Men | 141 |
| 1.08–1.60 | 443 |
| 1.04–1.34 | 635 |
| 1.06–1.31 | 809 |
| 1.02–1.25 | 1088 |
| 1.00–1.21 |
| Women | 31 |
| 1.26–2.82 | 78 |
| 1.02–1.80 | 111 |
| 1.06–1.77 | 142 |
| 1.02–1.66 | 183 | 1.22 | 0.97–1.54 |
| Kidney cancer | |||||||||||||||
| Men | 43 |
| 1.14–2.21 | 120 |
| 1.03–1.60 | 170 |
| 1.04–1.54 | 221 |
| 1.03–1.49 | 295 |
| 1.00–1.41 |
| Women | 24 | 1.53 | 0.98–2.40 | 67 | 1.22 | 0.90–1.65 | 85 | 1.09 | 0.82–1.45 | 117 | 1.11 | 0.86–1.44 | 164 | 1.13 | 0.89–1.44 |
|
| |||||||||||||||
|
|
|
|
|
|
| ||||||||||
|
|
|
|
|
| |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Lung cancer | |||||||||||||||
| Men | 318 | 1.11 | 0.93–1.32 | 1076 | 1.06 | 0.96–1.17 | 1872 | 1.04 | 0.96–1.13 | 2793 | 1.07 | 0.99–1.15 | 4355 |
| 1.01–1.15 |
| Women | 41 | 1.19 | 0.85–1.65 | 109 | 0.93 | 0.75–1.16 | 203 | 0.95 | 0.80–1.13 | 301 | 0.95 | 0.82–1.11 | 447 | 0.90 | 0.79–1.03 |
| Laryngeal cancer | |||||||||||||||
| Men | 42 | 1.27 | 0.89–1.82 | 122 | 1.05 | 0.84–1.30 | 213 | 1.07 | 0.89–1.28 | 342 |
| 1.00–1.35 | 504 | 1.10 | 0.96–1.26 |
| Women | 2 | 2.60 | 0.57–11.85 | 3 | 1.17 | 0.32–4.18 | 7 | 1.52 | 0.58–3.95 | 10 | 1.48 | 0.62–3.51 | 19 | 1.80 | 0.85–3.83 |
| Bladder cancer | |||||||||||||||
| Men | 92 |
| 1.15–1.86 | 257 | 1.14 | 0.98–1.32 | 461 |
| 1.01–1.29 | 659 | 1.10 | 0.99–1.23 | 1022 | 1.09 | 0.99–1.20 |
| Women | 15 |
| 1.00–2.95 | 35 | 1.14 | 0.78–1.66 | 80 |
| 1.05–1.85 | 116 |
| 1.01–1.68 | 174 | 1.22 | 0.97–1.54 |
| Kidney cancer | |||||||||||||||
| Men | 25 |
| 1.00–2.30 | 79 |
| 1.06–1.77 | 137 |
| 1.09–1.66 | 194 |
| 1.07–1.56 | 279 |
| 1.00–1.41 |
| Women | 13 | 1.49 | 0.83–2.67 | 36 | 1.18 | 0.81–1.71 | 61 | 1.08 | 0.79–1.47 | 98 | 1.15 | 0.87–1.50 | 160 | 1.19 | 0.94–1.51 |
Models were estimated separately for each type of cancer and for the different cut-off points of the exposure variable. * Group 1 substances: arsenic and compounds, benzene, benzo(a)pyrene, cadmium and compounds, polycyclic aromatic hydrocarbons, nickel and compounds, polychlorinated dibenzo-p-dioxins + polychlorinated dibenzofurans (PCDD + PCDF), particulate matter (PM10) and trichloroethylene. ** Group 2A substances: lead and compounds and tetrachloroethylene. Statistically significant results are in bold. IARC— International Agency for Research on Cancer.